Australian Drug Regulators Consider Order To Withdraw GSK's Avandia
This article was originally published in PharmAsia News
Australia's drug regulator is considering removal of U.K.-based GlaxoSmithKline's Avandia (rosiglitazone) from the national market because of a link to heart attacks
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.